Skip to main content
. 2021 Aug 16;10(17):5866–5877. doi: 10.1002/cam4.4137

FIGURE 2.

FIGURE 2

Prescribing trends for the most prevalent treatment regimens per year. The 1L MM prescription proportion for the combined aCD38 groups (aCD38 + PI + steroid, aCD38 + PI + IMID + steroid and aCD38 + IMID + steroid) were 0.1% for diagnosis in 2016, 0.1% for diagnosis in 2017, 0.4% for diagnosis in 2018 and 3% for diagnosis in 2019. 1L, front‐line; chemo, chemotherapy; IMiD, immunomodulatory drug; MM, multiple myeloma; PI, proteasome inhibitor